Lab scientists explain how they tell deamidation and racemization byproducts apart from the main drug, using high-resolution MS and 2D-LC.
Recap by typeshit. Full story at LCGC International.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Grocery Dive reports the supermarket chain is adding guided store tours built for shoppers taking GLP-1 medications.
Now CMO at CORXEL, Liang tells PharmExec he sees GLP-1s as a platform for heart, kidney and liver disease, with obesity only one piece of it.
Loading…